Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00351611 · ClinicalTrials.gov registry record · Phase 4
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 187
- Enrollment target
NCT00351611 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 187 participants.
The verdict
NCT00351611, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 187 participants
- Enrollment target
Study Summary
Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months. Neither the study doctor nor the patient will know the medication assignment. Vision testing will be performed prior to receiving the study treatment and at the end of the study to see if there are any changes.
Interventions
- DRUG placebo
- DRUG Lyrica (pregabalin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2006-07-26 |
| Est. Completion | 2020-02-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00351611
The ClinicalTrials.gov registry entry for NCT00351611 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00351611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00351611 about?
NCT00351611 is a clinical study titled "Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo". Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months. Neither the study doctor nor the patient will know the medication assignment....
What is the current status of trial NCT00351611?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 187 participants. The study started on 2006-07-26. Estimated completion is 2020-02-04.
What interventions are being tested in trial NCT00351611?
The interventions under investigation include: placebo (DRUG), Lyrica (pregabalin) (DRUG).
Who is sponsoring clinical trial NCT00351611?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.